Patents by Inventor Michael J. Bienkowski

Michael J. Bienkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alzheimer's disease, secretase, app substrates therefor, and uses therefor
    Publication number: 20030077226
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Application
    Filed: June 27, 2001
    Publication date: April 24, 2003
    Inventors: Mark E Gurney, Michael J Bienkowski, Robert L Heinrikson, Luis A Parodi, Riqiang Yan
  • TNF-related death ligand
    Publication number: 20030044937
    Abstract: The invention relates to a novel tumor necrosis factor (TNF) homolog designated herein as TNF-related death ligand (TRDL). Isolated nucleic acid molecules are provided which encode TRDL. TRDL polypeptides are also provided, as are methods for identifying agonists and antagonists of TRDL activity.
    Type: Application
    Filed: June 19, 2002
    Publication date: March 6, 2003
    Inventors: Michael J. Bienkowski, Cynthia J. Mills, David A. Jones
  • Aspartyl protease 2 (Asp2) antisense oligonucleotides
    Patent number: 6500667
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: April 18, 2000
    Date of Patent: December 31, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Alzheimer's disease secretase, APP substrates therefor, and uses therefor
    Patent number: 6440698
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: August 27, 2002
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • TNF-related death ligand
    Patent number: 6440694
    Abstract: The invention relates to a novel tumor necrosis factor (TNF) homolog designated herein as TNF-related death ligand (TRDL). Isolated nucleic acid molecules are provided which encode TRDL. TRDL polypeptides are also provided, as are methods for identifying agonists and antagonists of TRDL activity.
    Type: Grant
    Filed: September 21, 1998
    Date of Patent: August 27, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Michael J. Bienkowski, Cynthia J. Mills, David A. Jones
  • Alzheimer's disease secretase, APP substrates therefor, and uses thereof
    Patent number: 6420534
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: July 16, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Alzheimer's disease secretase, APP substrates therefor, and uses therefor
    Publication number: 20020081634
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Application
    Filed: April 5, 2001
    Publication date: June 27, 2002
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Alzheimer's disease secretase, APP substrates therefor, and uses therefor
    Publication number: 20020064819
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Application
    Filed: February 27, 2001
    Publication date: May 30, 2002
    Applicant: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Alzheimer's disease secretase, APP substrates therefor, and uses therefor
    Publication number: 20020037315
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Application
    Filed: February 27, 2001
    Publication date: March 28, 2002
    Applicant: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Alzheimer's disease secretase, APP substrates therefor, and uses therefor
    Publication number: 20010021391
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Application
    Filed: February 27, 2001
    Publication date: September 13, 2001
    Applicant: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Alzheimer's disease secretase, APP substrates therefor, and uses therefor
    Publication number: 20010018208
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Application
    Filed: February 28, 2001
    Publication date: August 30, 2001
    Applicant: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Alzheimer's disease secretase, APP substrates therefor, and uses therefor
    Publication number: 20010016324
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Application
    Filed: February 27, 2001
    Publication date: August 23, 2001
    Applicant: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Sequences of p56, proteins which affect K-ATP channels
    Patent number: 6031089
    Abstract: This invention describes the full length sequence of human p56 protein (p56-1), a related homolog (p56-2) and the nucleic acids that code for these proteins. The sequences are provided in Charts 1, 2, 3, and 4 and the sequence listings of the application.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: February 29, 2000
    Assignee: Pharmacia & Upjohn Company
    Inventor: Michael J. Bienkowski
  • DNA encoding a novel kidney ATP-dependent potassium channels
    Patent number: 5831055
    Abstract: The present invention comprises human DNA compositions, including cDNA clones, with full sequences, called, KIRK-2 and KIRK-3, encoding proteins that confer potassium channel activity to membranes or recipient cell lines. The DNA compositions include structural genes coding for the potassium channel proteins, expression and replication plasmids or vectors containing the structural genes and host cells expressing those genes. Methods of screening compounds for potassium channel modulating activity are also described.
    Type: Grant
    Filed: September 9, 1996
    Date of Patent: November 3, 1998
    Assignee: Pharmacia & Upjohn Company
    Inventor: Michael J. Bienkowski